Complete Response, Harmonization, INDs Rank On FDA Regulatory Agenda
Executive Summary
Complete response: FDA plans to finalize its proposed rule to replace "approvable"/"not approvable" letters in response to NDAs with complete response letters in October, according to HHS' spring "unified agenda." The rule is intended to fulfill the 1997 FDA Modernization Act requirement to discontinue "approvable"/"not approvable" letters in favor of a standard format. While complete response letters will still identify deficiencies in an application, they are believed less likely to create overreaction by investors. The proposed rule was issued in July 2004 (1"The Pink Sheet" July 26, 2004, p. 10)...
You may also be interested in...
FDA PDUFA Performance Hampered By Inadequate Staffing – OND’s Jenkins
Staffing issues are affecting FDA performance goals as the agency enters the fourth iteration of the Prescription Drug User Fee Act
FDA PDUFA Performance Hampered By Inadequate Staffing – OND’s Jenkins
Staffing issues are affecting FDA performance goals as the agency enters the fourth iteration of the Prescription Drug User Fee Act
FDA Regs On Experimental Drug Access May Be Loosened After Court Loss
FDA's ongoing development of rules for expanded access programs will likely take a broader approach after the agency's current standards were questioned by an appeals court